Cellular Biomedicine Group Inc., of Shanghai, said it closed two private placement transactions selling an aggregate of 1.2 million shares to selected key executives and private investors at $12 each, for total gross proceeds of approximately $14.5 million. The company intends to use the proceeds to fund clinical trials, invest in new product development and expand their research and development programs. Read More
PERTH, Australia – A Senate inquiry on research funding models for cancers with low survival rates has returned a report that outlines 25 recommendations to improve infrastructure, clinical trials and reimbursement processes for cancer drugs in Australia. Read More
Lowering brain levels of urea and/or ammonia might be a viable new therapeutic target for Huntington's disease (HD), according to the findings of a New Zealand study reported in the Dec. 11, 2017, online edition of Proceedings of the National Academy of Sciences. Read More
HONG KONG – Roivant Sciences Ltd., of Basel, Switzerland, has inked a $502.5 million deal for an autoimmune treatment developed by South Korea's Hanall Biopharma Co. Ltd. Read More
SHANGHAI – Zai Labs Ltd., of Shanghai, nabbed greater China rights for FPA-144, a first-in-class fibroblast growth factor (FGF) monoclonal antibody for gastric and gastroesophageal junction cancer being developed globally by Five Prime Therapeutics Inc., of San Francisco. Read More
HONG KONG – Nagoya, Japan-based Askat Inc. has signed a $1.2 billion licensing deal for two of its immune-oncology compounds with Arrys Therapeutics Inc., of Cambridge, Mass. Arrys was granted research, development and marketing rights for Askat's two prostaglandin E2 receptor 4 (EP4) antagonists, AAT-007 and AAT-008, in the global market excluding China. Read More
HONG KONG – I-Mab Biopharma has entered a $548 million licensing agreement with Genexine Inc. for an immuno-oncology drug candidate. Shanghai-based I-Mab will receive exclusive development and commercialization rights to Genexine's Hyleukin in Mainland China, Taiwan, Hong Kong and Macau. Genexine, of Seoul, South Korea, will receive an up-front payment of $12 million and the rest through royalties based on net sales of Hyleukin, plus milestone payments from I-Mab. Read More